source
- Priovant's Lisraya receives first FDA approval as oral therapy for dermatomyositisThe U.S. Food and Drug Administration has cleared Priovant Therapeutics' daily TYK2/JAK1 inhibitor tablet, marketed under the name Lisraya, for the treatment of dermatomyositis in adults. Lisraya…
- AstraZeneca and Ionis gene silencer Wainua fails trial after patients also took Pfizer heart drugAt the ESC Congress in Munich, a high‑profile trial of the gene‑silencing therapy Wainua, developed by AstraZeneca and Ionis, was reported to have failed. The failure was linked to participants co…